BIOPHYTIS: insider trades · France · AMF

About BIOPHYTIS

Biophytis SA is a French biotechnology company focused on developing innovative therapies for age-related diseases, with a core mission of preserving mobility, muscle function, and patient independence. Founded in 2006, the company emerged from an academic research project centered on the biology of aging and has since built a scientific platform dedicated to healthy longevity. Biophytis is headquartered in France and operates through an international footprint that includes clinical, regulatory, and partnership activities across Europe, the United States, Brazil, and Asia. Its business model is centered on BIO101, also known as 20-hydroxyecdysone, a small-molecule drug candidate being developed for multiple indications. The most advanced program targets sarcopenia, an age-related loss of muscle mass and strength in older adults, where Biophytis aims to establish BIO101 as a differentiated therapeutic option in a still underserved market. The company is also developing BIO101 in obesity, specifically addressing the muscle-wasting complications associated with obesity, which broadens the clinical and commercial opportunity for the asset. In parallel, Biophytis has launched a longevity research platform, enhanced by artificial intelligence, to identify new therapeutic candidates and expand beyond BIO101. Biophytis is best described as a clinical-stage biotech, meaning its valuation and strategic progress depend heavily on trial execution, regulatory milestones, and access to financing. The company does not yet have a marketed product and therefore remains exposed to the inherent risks of drug development, including clinical uncertainty, regulatory delays, and capital needs. In 2025 and 2026, Biophytis reported a number of strategic steps, including regulatory progress in sarcopenia and obesity, as well as financing and development partnerships in Asia and Latin America. These initiatives underline the company’s ambition to build an international growth platform around longevity and muscle-health therapeutics. Notable features of Biophytis include its strong positioning within the longevity theme, its narrow focus on frailty and muscle-loss disorders, and its partnership-led strategy to accelerate both research and future commercialization. As such, Biophytis stands out among French biotech companies for its specialization in the biology of aging and related therapeutic opportunities.